A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression
First and only PARP inhibitor to improve invasive disease-free survival in patients
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Bringing next-gen cannabinoid therapeutics to cancer patients
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
Subscribe To Our Newsletter & Stay Updated
